Navigation Links
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide,” Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international Phase IIb study with the TGF-beta 2-inhibitor AP 12009, under development by Antisense Pharma. Prof. Wong discussed the results of the study in the poster discussion session on central nervous system tumors at the 43rd Annual Meeting of the American Society of Clincal Oncology (ASCO) in Chicago, USA, this month.

The Phase IIb study AP 12009-G004 is an open-label, randomized, actively-controlled, parallel-group dose-finding study to evaluate the efficacy and safety of two doses of AP 12009 in adult patients with recurrent high-grade glioma. Efficacy endpoints were tumor response assessed by central blinded MRI reading and survival. At 29 international clinical centers 134 evaluable patients (39 with anaplastic astrocytoma, AA, WHO grade III and 95 with glioblastoma, GBM, WHO grade IV) have been randomized to three arms: AP 12009 10 ?M, AP 12009 80 ?M and chemotherapy (Temozolomide or PCV) as a control. AP 12009 was administered intratumorally via one catheter as continuous high-flow microperfusion over a 7-day period every other week for up to 6 months on an outpatient treatment basis (1, 2). Post-study follow-up for survival, long-term tumor response, and safety is still ongoing. Analysis of the core phase for AA patients is completed.

Tumor response was assessed according to Macdonald criteria. The response rate for AP 12009 10 ?M in anaplastic astrocytoma patients steadily increased in the course of 14 months, whereas in the chemotherapy treatment arm a transient peak of the response rate at 6 months was not sustainable and decreased to zero at 14 months. Response rates were higher in the AP 12009 10 ?M group compared to the AP 12009 80 ?M group. The
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:4/17/2015)... DIEGO , April 17, 2015  Trovagene, ... diagnostics, announced today that clinical data presented at ... that its urine-based Precision Cancer Monitoring ℠ ... and monitoring of EGFR T790M mutations ... Detection of EGFR T790M Mutation in Urinary ...
(Date:4/17/2015)... DUBLIN , Apr. 17, 2015 Research and ... addition of the "Medical Oxygen Systems - Global ... This report analyzes the worldwide markets for Medical ... Oxygen Concentrators, Liquid Oxygen Systems, Oxygen Cylinders & Regulators, ... analytics for the US, Canada , ...
(Date:4/17/2015)... -- Today, the Pharmaceutical Research and Manufacturers of ... companies as "We Work For Health Champions" for ... service. Established in 2009, the We ... the biopharmaceutical industry to honor employees who have ... also shown an outstanding commitment to their communities ...
Breaking Medicine Technology:Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3
... Water Street Healthcare Partners , a strategic private equity ... it has acquired MarketLab, Inc.  Water Street,s ... specialty healthcare distribution sector.  The acquisition expands Water Street,s ... life sciences, medical devices and services to 13. ...
... -- Dehaier Medical Systems Ltd. (NASDAQ: ... in the development, assembly, marketing and sale of medical ... that it was granted three new patents by State ... ("SIPO"). The patent awards were related to the design ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3
(Date:4/18/2015)... Omaha, NE (PRWEB) April 18, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the South Carolina Physical Therapy Association ... at the Kroc Center in Greenville, SC. ... networking opportunities, and exhibits with products and services. ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 PHOENIX, ARIZONA ... County, along with 11 other secure destruction professionals across ... Destruction Specialists (CSDS). He will now display “CSDS” as ... were offered before the National Association of Information Destruction ... and another Grapevine, Texas. Of the 20 people who ...
(Date:4/17/2015)... (PRWEB) April 18, 2015 Heritage Woods ... begin its Supportive Living Week Celebration on April 20 ... having a healthy mind, body and soul. , The ... McLeansboro, Illinois, serves older adults of all incomes, including ... their independence. , Supportive Living Week is observed every ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Riviera ... Dr. Kevin Sadati of the Gallery of Cosmetic ... County’s top beauty experts. The publication focused on ... facial stem cell fat grafting, eyelid surgery, laser resurfacing ... facial plastic surgery has resulted in thousands of ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... (Nasdaq: AMGN ) will present at the ... May 18, 2009 at the InterContinental, Boston, Mass., beginning ... Executive Officer Kevin Sharer will present. Live audio of ... can be accessed from Amgen,s Web site, www.amgen.com ...
... risk by 35%, study finds , , WEDNESDAY, May ... medications may ease the symptoms of bronchiolitis -- a ... research suggests this treatment may reduce the risk of ... wheezing sooner and get babies back to normal feeding ...
... Plan Yields Positive ResultsCLEVELAND, May 13 DATATRAK International, ... services company focused on global eClinical solutions for the ... the first quarter of 2009. Revenue for the first ... to $2,088,000 in the same period of 2008. Gross ...
... VIEW, Calif., May 13 MAP Pharmaceuticals, Inc. (Nasdaq: ... at the Deutsche Bank Securities 34th Annual Health ... (ET) in Boston, MA.A live webcast of the presentation will ... website at http://www.mappharma.com . A replay will also be ...
... from a study of managed-care cancer patients receiving chemotherapy ... the cumulative ESA cost with Epoetin alfa (EPO) was ... The analysis, published in the Spring issue of ... by Centocor Ortho Biotech Services, LLC. The retrospective ...
... a lawsuit against the U.S. Patent and Trademark Office and Myriad ... as BRCA1 and BRCA2, which are indicators for hereditary predisposition to ... ... May 13, 2009 -- The College of American Pathologists today joined ...
Cached Medicine News:Health News:Combo Treatment Eases Wheezing in Babies 2Health News:Combo Treatment Eases Wheezing in Babies 3Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 2Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 3Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 4Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 5Health News:DATATRAK International, Inc. Announces First Quarter Results for 2009 6Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 2Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 3Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 4Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 5Health News:Retrospective Analysis Finds Treatment of Cancer Chemotherapy Patients With Epoetin Alfa Associated With Lower Drug Cost Than Darbepoetin Alfa 6Health News:CAP Joins Landmark Lawsuit Challenging Legality of Myriad Genetics Gene Patents 2
... Choose from a complete ... and AC halogen light ... cool illumination. A solid-state ... intensity, and our exclusive ...
Inquire...
... inverted microscope technology that offers you much more ... in this category. You will be impressed by ... been designed to make lab work as easy ... efficiency of your workflow. Your advantage: more time ...
... represents the most advanced motorized inverted microscope ... and optical design provides 9 access ports ... to four ports can have simultaneous access ... motorized Z-axis drive, 6-position nosepiece and light ...
Medicine Products: